Catalog #CP206
RecombiMAb anti-mouse CD3ε (D265A)
Clone
145-2C11-CP206
Reactivities
Mouse
Applications
in vitro T cell stimulation/activation
in vivo T cell stimulation/activation
Immunofluorescence
Flow cytometry
Western blot
in vivo T cell stimulation/activation
Immunofluorescence
Flow cytometry
Western blot
Isotype
Mouse IgG1 (D265A), κ
(switched from Armenian Hamster IgG1)
(switched from Armenian Hamster IgG1)
You may also be interested in:
Product Description
The 145-2C11-CP206 monoclonal antibody is a recombinant, Fc-engineered chimeric version of the original 145-2C11 antibody. The variable domain sequences are identical but the constant region sequences have been switched from hamster IgG1 to mouse IgG1, κ for use in murine models. Additionally, 145-2C11-CP206 contains the Fc-silencing mutation D265A. This antibody is also referred to in the literature as “2C11-Novi” and is used as a surrogate murine antibody to model anti-human CD3 therapies. Studies have demonstrated recombinant, Fc-silent 145-2C11 minimizes T-cell depletion, cytokine‑release and acute toxicity while retaining CD3‑TCR downregulation, T-cell killing and immunosuppressive function. Species-matched chimeric antibodies demonstrate reduced immunogenicity and formation of anti-drug antibodies (ADAs) compared to xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.
The 145-2C11-CP206 monoclonal antibody reacts with mouse CD3ε, a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily. CD3ε is one of five polypeptide chains that combine to form the TCR complex. CD3ε is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes. CD3 plays roles in TCR signaling, T lymphocyte activation, and antigen recognition. Additionally, the 145-2C11 antibody has been reported to block the binding of the 17A2 antibody to CD3ε+ T lymphocytes.
References:
Alegre, M L et al. “An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.” Journal of immunology (Baltimore, Md. : 1950) vol. 155,3 (1995): 1544-55.
Dépis, Fabien et al. “Characterization of a surrogate murine antibody to model anti-human CD3 therapies.” mAbs vol. 5,4 (2013): 555-64. doi:10.4161/mabs.24736
Dépis F, Hatterer E, Lamacchia C, Waldburger JM, Gabay C, Reith W, Kosco-Vilbois M, Dean Y. Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum. 2012 Oct;64(10):3189-98. doi: 10.1002/art.34497. PMID: 22508436.
The 145-2C11-CP206 monoclonal antibody reacts with mouse CD3ε, a 20 kDa transmembrane cell-surface protein that belongs to the immunoglobulin superfamily. CD3ε is one of five polypeptide chains that combine to form the TCR complex. CD3ε is expressed on T lymphocytes, NK-T cells, and to varying degrees on developing thymocytes. CD3 plays roles in TCR signaling, T lymphocyte activation, and antigen recognition. Additionally, the 145-2C11 antibody has been reported to block the binding of the 17A2 antibody to CD3ε+ T lymphocytes.
References:
Alegre, M L et al. “An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.” Journal of immunology (Baltimore, Md. : 1950) vol. 155,3 (1995): 1544-55.
Dépis, Fabien et al. “Characterization of a surrogate murine antibody to model anti-human CD3 therapies.” mAbs vol. 5,4 (2013): 555-64. doi:10.4161/mabs.24736
Dépis F, Hatterer E, Lamacchia C, Waldburger JM, Gabay C, Reith W, Kosco-Vilbois M, Dean Y. Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum. 2012 Oct;64(10):3189-98. doi: 10.1002/art.34497. PMID: 22508436.
Specifications
| Isotype | Mouse IgG1 (D265A) |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | D265A |
| Immunogen | Mouse BM10-37 cytotoxic T cells |
| Reported Applications |
in vitro T cell stimulation/activation in vivo T cell stimulation/activation Immunofluorescence Flow cytometry Western blot |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from mammalian cell supernatant in an animal-free facility |
| Purification | Protein G |
| RRID | AB_3751652 |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |